Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium

Eileen S. Kim, Jennifer E. Kim, Mira A. Patel, Antonella Mangraviti, Jacob Ruzevick, Michael Lim

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations


Immune checkpoints have come to the forefront of cancer therapies as a powerful and promising strategy to stimulate antitumor T cell activity. Results from recent preclinical and clinical studies demonstrate how checkpoint inhibition can be utilized to prevent tumor immune evasion and both local and systemic immune suppression. This review encompasses the key immune checkpoints that have been found to play a role in tumorigenesis and, more specifically, gliomagenesis. The review will provide an overview of the existing preclinical and clinical data, antitumor efficacy, and clinical applications for each checkpoint with respect to GBM, as well as a summary of combination therapies with chemotherapy and radiation.

Original languageEnglish (US)
Article number4683607
JournalJournal of immunology research
StatePublished - 2016

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium'. Together they form a unique fingerprint.

Cite this